Sarepta Therapeutics (SRPT) reported $442.93 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 32.7%. EPS of -$3.58 for the same period compares to $1.50 a year ago.
The reported revenue represents a surprise of +8.42% over the Zacks Consensus Estimate of $408.53 million. With the consensus EPS estimate being -$0.71, the EPS surprise was -404.23%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Sarepta Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Revenues- Product, net: $369.61 million compared to the $382.54 million average estimate based on eight analysts. The reported number represents a change of -42.1% year over year.
- Revenues- Product, net- ELEVIDYS: $110 million versus the seven-analyst average estimate of $114.3 million. The reported number represents a year-over-year change of -71.4%.
- Revenues- PMO Products: $259 million compared to the $270.1 million average estimate based on seven analysts. The reported number represents a change of +2% year over year.
- Revenues- Collaboration: $73.33 million versus the seven-analyst average estimate of $25.24 million. The reported number represents a year-over-year change of +262%.
View all Key Company Metrics for Sarepta Therapeutics here>>>
Shares of Sarepta Therapeutics have returned -11% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Just Released: Zacks Top 10 Stocks for 2026
Hurry – you can still get in early on our 10 top tickers for 2026. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful.
From inception in 2012 through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.
Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2026. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
